Hospices Civils de Lyon (CHU)

Motorized spiral enteroscopy: Results of an international multicenter prospective observational clinical study in patients with normal and altered gastrointestinal anatomy (2022) Beyna T, Moreels T, Arvanitakis M, Pioche M, Saurin JC, May A, Knabe M, et al. Journal article The CAR-HEMATOTOX model identifies patients with a high risk for CAR T-cell related hematotoxicity and is associated with prolonged hospitalization and poor prognosis (2021) Rejeski K, Perez A, Sesques P, Berger C, Jentzsch L, Mougiakakos D, Froelich L, et al. Conference contribution Clinical phenotypes of CAR-T-cell related hematotoxicity in relapsed/refractory large B-cell lymphoma (2021) Rejeski K, Sesques P, Berger C, Jentzsch L, Mougiakakos D, Froelich L, Bucklein , et al. Conference contribution Current clinical practice of prenatal dexamethasone treatment in at risk pregnancies for classic 21-hydroxylase deficiency in Europe (2021) Nowotny HF, Neumann U, Tardy-Guidollet V, Ahmed SF, Baronio F, Battelino T, Bertherat J, et al. Conference contribution Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? (2021) Ho K, Fleseriu M, Kaiser U, Salvatori R, Brue T, Lopes MB, Kunz P, et al. Journal article The aetiologies of epilepsy (2021) Balestrini S, Arzimanoglou A, Blümcke I, Scheffer IE, Wiebe S, Zelano J, Walker MC Journal article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, et al. Journal article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, et al. Journal article PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (2021) Girard N, Smit HJM, Sibille A, Mcdonald F, Mornex F, Garassino MCC, Filippi AR, et al. Conference contribution Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section (2021) Ng S, Messerer M, Engelhardt J, Bruneau M, Cornelius JF, Cavallo LM, Cossu G, et al. Journal article, Review article